Coherus Oncology, Inc. (CHRS)

Executive Summary / Key Takeaways

• A Complete Transformation: Coherus Oncology has executed a radical pivot from biosimilars to pure-play oncology, reducing debt by 90% to $38.8 million and funding a clinical pipeline through the $483 million UDENYCA divestiture, creating a streamlined immuno-oncology company with 18-24 months of cash runway through key catalysts.

• LOQTORZI's Defensible Monopoly: The company's next-generation PD-1 inhibitor holds the only FDA approval for nasopharyngeal carcinoma (NPC) and is now the sole NCCN Category 1 preferred first-line treatment, with 113% revenue growth to $40.8 million in 2025 and a clear trajectory to $175 million annually by 2028, representing 70% market share of a $250 million market.

• Pipeline Catalysts in 2026: Two mid-stage assets—tagmokitug (anti-CCR8) and casdozokitug (anti-IL-27)—are positioned as best-in-class and first-in-class respectively, with initial efficacy data expected in the first half of 2026 that could validate LOQTORZI as a revenue multiplier through combination therapies and unlock ex-U.S. partnership opportunities.

• Path to Profitability by 2027: Management has established precise financial milestones: $15-16 million quarterly LOQTORZI sales covers commercial costs (expected 2026), and $30-35 million quarterly sales covers core operating burn (expected 2027), creating a self-funding model that eliminates dilution risk if execution holds.

• Critical Execution Risks: The thesis hinges on converting NCCN guideline preference into community oncology adoption, competing against off-label Keytruda use, and delivering positive Phase 2 data for pipeline assets while managing a 35% headcount reduction that could strain commercial momentum during a crucial growth phase.

Setting the Scene: From Biosimilar Conglomerate to Oncology Pure-Play

Coherus Oncology, originally incorporated as Coherus BioSciences in September 2010 and headquartered in Redwood City, California, spent its first decade building a biosimilar franchise anchored by UDENYCA, a Neulasta biosimilar that reached $240 million in annual sales. This history established the company's manufacturing expertise and commercial infrastructure, providing the financial resources for a strategic rebirth. By 2023, management recognized that competing in commoditized biosimilars against pharmaceutical giants offered limited upside, while their oncology pipeline—bolstered by the September 2023 acquisition of Surface Oncology—presented a path to differentiated, high-margin innovation.

The transformation was surgical and swift. Between March 2024 and April 2025, Coherus divested its entire biosimilar portfolio: CIMERLI for $153.8 million, YUSIMRY for $22.8 million, and finally UDENYCA for $483.4 million in cash. This sequence of transactions was a coordinated exit that maximized value at each step. The UDENYCA deal, completed in April 2025, included $118.4 million for inventory and two potential $37.5 million earn-out payments if sales exceed $300-350 million thresholds—effectively giving Coherus continued upside while eliminating operational risk. The proceeds funded a 90% debt reduction, from $480 million to $38.8 million, and left the company with $172 million in cash at year-end 2025, plus an additional $47 million raised in a February 2026 equity offering.

This balance sheet repair fundamentally alters the risk/reward profile. A company that once carried leverage typical of mature pharma is now capitalized like a clinical-stage biotech with commercial revenue. The 35% headcount reduction, from 228 to 147 employees, further streamlined operations, yielding $30 million in annualized savings. Consequently, Coherus can now fund its pipeline through LOQTORZI growth rather than dilutive equity raises, and any positive data readout in 2026 could be monetized through partnerships without financial desperation. The transformation from a hybrid biosimilar/oncology company to Coherus Oncology, officially renamed on May 29, 2025, created a clean investment story with a single focus: immuno-oncology leadership.

Technology, Products, and Strategic Differentiation: Building a Revenue Multiplier

LOQTORZI: The Only Approved PD-1 for NPC

LOQTORZI (toripalimab-tpzi) is the only FDA-approved treatment for metastatic or recurrent locally advanced nasopharyngeal carcinoma, launched in January 2024. This exclusivity creates a regulatory moat that off-label competitors cannot easily breach. While Keytruda (MRK), Opdivo (BMY), and other PD-1s are widely used across oncology, none have FDA approval for NPC, forcing physicians to choose between guideline-recommended therapy and familiar but unapproved alternatives. The NCCN guidelines have reinforced this advantage twice: first in December 2023 making LOQTORZI a preferred Category 1 option, then in November 2024 specifying it as the only preferred Category 1 first-line treatment when combined with cisplatin and gemcitabine.

The clinical data supporting this positioning is exceptional. Six-year overall survival follow-up from the JUPITER-2 trial, presented at ESMO Asia in December 2025, showed patients on LOQTORZI plus chemotherapy achieved a median survival of 64.8 months—nearly double the 33.7 months for chemotherapy alone, representing a 31-month improvement. This magnitude of benefit gives community oncologists, who see NPC patients infrequently, a compelling reason to follow guidelines rather than default to familiar Keytruda regimens. The survival advantage translates directly to commercial pull-through, driving the 113% revenue growth to $40.8 million in 2025 and positioning the product for peak market share of 70% in a $250 million market.

Tagmokitug: Best-in-Class CCR8 Targeting

Tagmokitug (CHS-114) is an afucosylated IgG1 antibody targeting CCR8, a chemokine receptor highly expressed on regulatory T cells (Tregs) within the tumor microenvironment. The afucosylation enhances antibody-dependent cellular cytotoxicity, creating a more potent Treg depletion mechanism than competing antibodies. Management emphasizes that CHS-114 is a selective CCR8 antibody, with competitors showing off-target binding that could cause toxicity. This selectivity could enable higher dosing, broader combinability, and a cleaner safety profile, all critical for a drug intended to be used with PD-1 inhibitors and other immuno-oncology agents.

The strategic rationale for targeting Tregs is compelling. Tregs are associated with poor prognosis and can be upregulated by anti-cancer treatments, creating a resistance mechanism that limits PD-1 efficacy. By depleting intra-tumoral Tregs, tagmokitug could restore or enhance immune responses, making it a valuable combination partner. The Janssen (JNJ) collaboration to evaluate tagmokitug with pasritamig (a T-cell engaging bispecific) in metastatic castration-resistant prostate cancer validates this strategy, positioning Coherus as a preferred partner for Treg depletion. Initial data in head and neck squamous cell carcinoma, upper GI adenocarcinoma, and colorectal cancer expected in mid-2026 will test whether this biology translates to clinical benefit.

Casdozokitug: First-in-Class IL-27 Antagonism

Casdozokitug (CHS-388) targets IL-27, an immune regulatory cytokine overexpressed in hepatocellular carcinoma (HCC), lung, and renal cell carcinoma. The company is pursuing a novel mechanism with an IL-27 antagonist, creating potential first-mover advantage. IL-27 plays a key role in immune responses within barrier tissues, and casdozokitug's ability to activate NK cells provides a mechanistic explanation for increased complete response rates observed in early studies. The FDA granted orphan drug designation for HCC in October 2020, potentially enabling a faster development path and market exclusivity.

The ongoing Phase 2 study in first-line HCC combines casdozokitug with LOQTORZI and bevacizumab, positioning it as a triple therapy that could improve upon standard-of-care combinations. Data expected in mid-2026 will determine whether this first-in-class asset can expand LOQTORZI's utility beyond NPC into larger liver cancer markets. The global rights to both pipeline assets offer ex-U.S. partnership opportunities, which management expects to provide upfront payments and contribute to pivotal trial costs—potentially providing non-dilutive funding that further extends the cash runway.

Financial Performance & Segment Dynamics: Evidence of a Working Model

Revenue Growth Driven by LOQTORZI Momentum

Continuing operations revenue reached $42.17 million in 2025, up 59.8% year-over-year, with LOQTORZI contributing $40.84 million (97% of total). The 113% growth in LOQTORZI sales validates the commercial model in a rare disease setting where physician education is critical. Quarterly progression shows momentum: Q1 $7.3 million, Q2 $10.0 million (36% growth), Q3 $11.2 million (12% growth), and Q4 $12.4 million (11% growth). While the sequential growth rate moderated, management attributes Q1 softness to sales force restructuring and Q4 supply interruptions related to the UDENYCA transition—temporary headwinds that have since resolved.

The demand drivers are encouraging. New patient starts increased across both new and existing accounts, with purchasing accounts growing 11% in Q4. More importantly, a growing number of accounts are using LOQTORZI on subsequent patients, indicating repeat usage and physician confidence. NPC is a rare cancer treated by community oncologists who see few cases annually; converting them from off-label Keytruda requires both guideline support and positive real-world experience. The 15% field force expansion and addition of inside sales representatives targeting VA hospitals represent investments to deepen penetration, with management expecting 10-15% quarterly demand growth to continue.

Margin Structure and Path to Profitability

Gross margin held steady at 67% in both 2024 and 2025, demonstrating pricing power despite LOQTORZI being a new entrant. This margin stability shows the product is not being discounted to gain share, preserving capital for commercial investment. The operating loss from continuing operations narrowed from $215.4 million in 2024 to $183.1 million in 2025, driven by a $24.9 million reduction in SG&A expenses that offset a $17.1 million increase in R&D spending.

The SG&A reduction is particularly significant. Employee-related costs fell $11.9 million due to lower headcount, while professional fees dropped $5.4 million as the company shed biosimilar-related expenses. This demonstrates that management can scale the commercial infrastructure efficiently—critical for a company targeting a $250 million market that doesn't require a massive sales force. The R&D increase, focused on tagmokitug ($19.9 million) and casdozokitug ($14.5 million), represents investment in future revenue multipliers. With $172 million in cash and a quarterly burn rate of approximately $20 million (excluding one-time items), the company has 8-9 quarters of runway before needing additional capital, aligning with the mid-2026 data readout timeline.

Balance Sheet Transformation

The debt reduction from $480 million to $38.8 million is the most important financial development. By repaying the 2026 Convertible Notes and buying out UDENYCA royalty rights for $47.7 million, Coherus eliminated near-term maturity risk and freed up cash flow. The remaining $38.7 million 2029 Term Loan carries minimal interest expense, and the company is eligible for two $37.5 million earn-out payments if UDENYCA sales exceed thresholds through Q1 2027. This transforms Coherus from a leveraged, diversified biopharma into a focused oncology company with net debt of negative $133 million (cash exceeds debt), providing strategic flexibility to fund development or pursue accretive acquisitions.

The February 2026 equity raise of $47 million, while dilutive, was modest relative to the cash position and specifically earmarked for LOQTORZI commercial expansion and pipeline advancement. Management's decision to raise capital at this stage suggests they see near-term catalysts that could make the stock more expensive later, or they want to ensure sufficient cushion to negotiate from strength in potential partnership discussions.

Outlook, Management Guidance, and Execution Risk

LOQTORZI Revenue Milestones

Management has provided specific financial targets that create a clear investment framework. At $15-16 million quarterly sales (approximately $60-64 million annualized), LOQTORZI will cover its own commercial costs and begin contributing to corporate SG&A. This implies reaching profitability on a segment basis by late 2026, given Q4 2025 sales of $12.4 million and projected 10-15% quarterly growth. At $30-35 million quarterly sales ($120-140 million annualized), LOQTORZI will cover the company's core burn excluding clinical trial expenses, expected in 2027.

These milestones provide tangible proof points for execution. Unlike typical biotech guidance that focuses solely on pipeline events, Coherus has built a self-funding model where commercial success directly funds innovation. The $175 million peak revenue target by 2028, representing 70% share of a $250 million NPC market, is achievable if the company can convert community oncologists who currently use off-label Keytruda. The recent NCCN update making LOQTORZI the only preferred regimen provides a powerful tool for the expanded sales force, potentially accelerating adoption beyond the current 10-15% quarterly growth rate.

Pipeline Catalysts and Partnership Strategy

Initial data readouts for tagmokitug and casdozokitug are expected in the first half of 2026, creating a near-term catalyst window. The head and neck squamous cell carcinoma cohort (40 patients) and upper GI adenocarcinoma cohort (40 patients) will test whether tagmokitug can reverse PD-1 resistance, while the HCC study will evaluate casdozokitug's triple combination. These readouts will determine whether LOQTORZI becomes a true revenue multiplier or remains a single-indication asset. Positive data could trigger ex-U.S. partnerships that provide non-dilutive funding, while negative results would force management to prioritize programs and potentially conserve cash.

The Janssen collaboration for tagmokitug in prostate cancer is strategically significant beyond the immediate indication. It validates Coherus's scientific platform and positions the company as a partner of choice for Treg depletion, potentially leading to additional deals with other oncology players. Management indicates that more such relationships are in development, suggesting the Janssen deal is part of a broader strategy to monetize the CCR8 asset across multiple combinations.

Risks and Asymmetries: What Could Break the Thesis

Competitive Pressure from Off-Label PD-1 Use

The most immediate risk is physician preference for familiar PD-1 inhibitors despite guidelines. Community oncologists see a very small number of NPC patients every year and may default to treatments they have used previously. Keytruda plus chemotherapy is a real competitor in the community setting, even though NCCN guidelines explicitly recommend LOQTORZI. This could slow market penetration and delay the revenue milestones that underpin the self-funding model. The 15% field force expansion is designed to counter this through continuous physician engagement, but if conversion stalls, quarterly growth could fall below the 10-15% target, pushing profitability milestones to 2027 or beyond.

Pipeline Execution Risk

Tagmokitug and casdozokitug are both mid-stage assets with unproven efficacy. While the scientific rationale is compelling—Treg depletion to overcome resistance, IL-27 antagonism to activate NK cells—Phase 2 data could fail to show meaningful clinical benefit. The CCR8 class has shown limited single agent activity, making combination success essential. If mid-2026 readouts are negative, Coherus would be left with a single-product company valued at 6.15x sales, likely requiring significant restructuring. The $47 million equity raise in February 2026 signals that management wants a cash cushion ahead of these binary events.

Scale and Operational Disruption

The 35% headcount reduction, while necessary for cost control, creates execution risk during a critical growth phase. The Q1 2025 sales force restructuring impacted momentum, and any further turnover could disrupt customer relationships in a rare disease market where trust and continuity matter. Additionally, the company is executing a coordinated initiative to onshore biomanufacturing for all three products, a complex operational shift that could create supply disruptions or quality issues. At a scale of just 147 employees, Coherus lacks the redundancy of larger pharma companies, making it vulnerable to key personnel departures or manufacturing setbacks.

Market Size Limitations

The NPC market is capped at $250 million. Even achieving 70% share yields $175 million in peak sales—sufficient to fund operations but not enough to justify a multi-billion dollar valuation. LOQTORZI's true value depends on expanding into additional indications, but the company has not disclosed specific plans beyond NPC. If pipeline assets fail, Coherus would be a profitable but slow-growing oncology company, likely valued at a modest multiple of earnings rather than the current revenue multiple.

Valuation Context: Pricing in Execution

At $1.73 per share, Coherus trades at a $259 million market capitalization, or 6.15 times trailing sales of $42.2 million from continuing operations. This multiple reflects the market's expectation of continued LOQTORZI growth and positive pipeline catalysts. The enterprise value of $141.6 million (net of cash) implies an EV/Revenue multiple of 3.36x for a company with 59.8% revenue growth and a path to profitability.

The valuation metrics must be interpreted in context of the transformation. The negative operating margin of -339.5% includes $108.9 million in R&D spending that is discretionary and could be curtailed if pipeline assets underperform. The gross margin of 67.2% is the more relevant metric, showing that LOQTORZI can support a profitable commercial business once scale is achieved. With $172 million in cash and a quarterly burn of approximately $20 million, the company has 8-9 quarters of runway, sufficient to reach the mid-2026 data readouts and potentially achieve the $15-16 million quarterly revenue milestone that makes the commercial segment self-sustaining.

Comparing to peers, Merck trades at 4.6x sales with 32.8% operating margins, Bristol-Myers at 2.5x sales with 28.2% margins, and Amgen (AMGN) at 5.1x sales with 30.6% margins. Coherus's premium multiple reflects its growth rate (59.8% vs. single-digit peer growth) and the optionality of its pipeline. However, if LOQTORZI growth decelerates or pipeline data disappoints, the multiple could compress sharply. Conversely, positive Phase 2 data could justify a premium valuation as the market prices in expanded indications and partnership potential.

Conclusion: A Binary but Well-Defined Path Forward

Coherus Oncology has engineered a clean transformation, converting a mature biosimilar business into a focused immuno-oncology company with a commercially validated asset, a fortified balance sheet, and a pipeline of novel mechanisms approaching key inflection points. The investment thesis rests on three variables: LOQTORZI's ability to capture 70% of the NPC market by 2028, the pipeline's capacity to deliver positive data in mid-2026, and management's execution of a self-funding model that eliminates dilution risk.

The stock at $1.73 prices in successful execution of this plan but not extraordinary success. The 6.15x sales multiple is supported by 113% product growth and a clear path to profitability, while the $172 million cash position provides downside protection. The combination of near-term catalysts (2026 data) with a commercial trajectory could make the company self-sustaining regardless of pipeline outcomes. The risks involve the small scale of the organization and the competitive reality that even NCCN "only preferred" status hasn't fully displaced off-label Keytruda use.

For investors, the critical monitoring points are LOQTORZI quarterly growth rates and the quality of mid-2026 pipeline data. If both hold, Coherus could emerge as a rare example of a biotech that funded its growth through commercial execution rather than serial dilution. If either falters, the strong balance sheet provides time to pivot, but the valuation premium would likely evaporate. The transformation is complete; now the execution must prove it was worth the price.